Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 6/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801836 | 1.00 | HPGD (0.42) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6801833 | 1.00 | HPGD (0.42) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6801223 | 0.87 | ALDH1A1 (0.40) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6795854 | 0.87 | ALDH1A1 (0.40) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6796794 | 0.86 | KDM4E (0.42) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6796798 | 0.86 | KDM4E (0.42) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6796804 | 0.86 | KDM4E (0.42) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6701095 | 0.78 | ALDH1A1 (0.49) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6804689 | 0.78 | ALDH1A1 (0.49) | HPGDKDM4EHSD17B10ALDH1A1MEN1 | |
| SCHEMBL6804691 | 0.78 | ALDH1A1 (0.49) | HPGDKDM4EHSD17B10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044013-A1 | 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors | IBFB GMBH PRIVATES INSTITUT FUR BIOMEDIZINISCHE FORSCHUNG UND BERATUNG (DE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044013-A1 | 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors | MMP2, MMP3, MMP1 | HPGD 132/4885KDM4E 1675/4885HSD17B10 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.